214 related articles for article (PubMed ID: 37038721)
1. Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population.
Fujiwara R; Yuasa T; Kobayashi K; Yoshida T; Kageyama S
Expert Rev Anticancer Ther; 2023 May; 23(5):461-469. PubMed ID: 37038721
[TBL] [Abstract][Full Text] [Related]
2. Developments in personalized therapy for metastatic renal cell carcinoma.
Fujiwara R; Kageyama S; Yuasa T
Expert Rev Anticancer Ther; 2022 Jun; 22(6):647-655. PubMed ID: 35531636
[TBL] [Abstract][Full Text] [Related]
3. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ
Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial.
Rha SY; Choueiri TK; Matveev VB; Alyasova A; Hong SH; Gordoa TA; Gurney H; Bjarnason GA; Buchler T; Pedrazzoli P; Takagi T; Park SH; Lee JL; Perini RF; He CS; McKenzie JA; Eto M
Int J Cancer; 2023 Sep; 153(6):1241-1250. PubMed ID: 37294085
[TBL] [Abstract][Full Text] [Related]
6. Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma.
Ged Y; Lee CH
Expert Rev Anticancer Ther; 2022 Oct; 22(10):1049-1059. PubMed ID: 36154355
[TBL] [Abstract][Full Text] [Related]
7. The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy.
Hamieh L; Beck RL; Le VH; Hsieh JJ
Clin Genitourin Cancer; 2020 Aug; 18(4):252-257.e2. PubMed ID: 32291161
[TBL] [Abstract][Full Text] [Related]
8. Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study.
Eto M; Takagi T; Kimura G; Fukasawa S; Tamada S; Miura Y; Oya M; Sassa N; Anai S; Nozawa M; Sakai H; Perini R; Yusa W; Ikezawa H; Narita T; Tomita Y
Cancer Med; 2023 Mar; 12(6):6902-6912. PubMed ID: 36457273
[TBL] [Abstract][Full Text] [Related]
9. Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma.
Yang Y; Psutka SP; Parikh AB; Li M; Collier K; Miah A; Mori SV; Hinkley M; Tykodi SS; Hall E; Thompson JA; Yin M
Cancer Med; 2022 Aug; 11(16):3106-3114. PubMed ID: 35304832
[TBL] [Abstract][Full Text] [Related]
10. The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma.
Jacob A; Shook J; Hutson T
Expert Rev Anticancer Ther; 2021 Apr; 21(4):365-372. PubMed ID: 33393393
[No Abstract] [Full Text] [Related]
11. Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma.
Spisarová M; Melichar B; Vitásková D; Študentová H
Expert Rev Anticancer Ther; 2021 Jul; 21(7):693-703. PubMed ID: 33794744
[No Abstract] [Full Text] [Related]
12. Combined use of pembrolizumab and lenvatinib: A review.
Eisinger C; Muluneh B
J Oncol Pharm Pract; 2023 Sep; 29(6):1461-1466. PubMed ID: 37231712
[TBL] [Abstract][Full Text] [Related]
13. Recent pharmacological approaches for the treatment of renal cell carcinoma.
Alimohammadi A; Fajkovic H; Remzi M; Shariat S; Schmidinger M
Expert Rev Clin Pharmacol; 2022 Feb; 15(2):187-195. PubMed ID: 35285369
[TBL] [Abstract][Full Text] [Related]
14. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
[TBL] [Abstract][Full Text] [Related]
15. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Motzer R; Alekseev B; Rha SY; Porta C; Eto M; Powles T; Grünwald V; Hutson TE; Kopyltsov E; Méndez-Vidal MJ; Kozlov V; Alyasova A; Hong SH; Kapoor A; Alonso Gordoa T; Merchan JR; Winquist E; Maroto P; Goh JC; Kim M; Gurney H; Patel V; Peer A; Procopio G; Takagi T; Melichar B; Rolland F; De Giorgi U; Wong S; Bedke J; Schmidinger M; Dutcus CE; Smith AD; Dutta L; Mody K; Perini RF; Xing D; Choueiri TK;
N Engl J Med; 2021 Apr; 384(14):1289-1300. PubMed ID: 33616314
[TBL] [Abstract][Full Text] [Related]
16. Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma.
Vitale MG; Nasso C; Oltrecolli M; Baldessari C; Fanelli M; Dominici M; Sabbatini R
Expert Rev Anticancer Ther; 2021 Nov; 21(11):1183-1192. PubMed ID: 34424125
[TBL] [Abstract][Full Text] [Related]
17. A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors.
Kitano S; Fujiwara Y; Shimizu T; Iwasa S; Yonemori K; Kondo S; Shimomura A; Koyama T; Ebata T; Ikezawa H; Hayata N; Minoshima Y; Miura T; Kubota T; Yamamoto N
Cancer Chemother Pharmacol; 2022 Dec; 90(6):523-529. PubMed ID: 36289094
[TBL] [Abstract][Full Text] [Related]
18. Case report: Abolishing primary resistance to PD-1 blockade by short-term treatment of lenvatinib in a patient with advanced metastatic renal cell carcinoma.
Tan T; Lin X; Ling J; Wang R; Chen Y; Cai L; Sun J; Wu D; Xie G
Front Immunol; 2023; 14():1115691. PubMed ID: 36742302
[TBL] [Abstract][Full Text] [Related]
19. Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies.
Motzer RJ; Taylor MH; Evans TRJ; Okusaka T; Glen H; Lubiniecki GM; Dutcus C; Smith AD; Okpara CE; Hussein Z; Hayato S; Tamai T; Makker V
Expert Rev Anticancer Ther; 2022 Apr; 22(4):383-400. PubMed ID: 35260027
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis.
Santoni M; Rizzo A; Mollica V; Rosellini M; Marchetti A; Fragomeno B; Battelli N; Massari F
Expert Rev Pharmacoecon Outcomes Res; 2022 Jan; 22(1):45-51. PubMed ID: 34058953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]